ERBB2 and breast cancer: Additionally, TGFβ transactivates EGFR in breast cancer [57] therefore removal of TGFβ stimulation in the mesHMLE subline attenuated EGFR/HER2 signalling as evidenced by the relative downregulation of EGF signalling ligands such as AREG in Fig. 3c.